Hutch News

Pancreatic researcher Sunil Hingorani joins Clinical faculty

Sept. 1, 2005

Dr. Sunil Hingorani, who studies the progression of pancreatic cancer, has joined the Clinical Research Division faculty.

Formerly an instructor of medicine and cancer biology and an attending physician in hematology/oncology at the University of Pennsylvania, Hingorani engineered the first mouse model of pancreatic cancer. The mice, which contain two gene mutations commonly found in human pancreatic cancer, display symptoms and disease progression that mimics pancreatic cancer in humans. The system opens the door to the discovery of new treatments as well as diagnostic tests for early detection of pancreatic cancer, one of the deadliest human malignancies.

"We are thrilled to have Sunil join us," said Dr. Fred Appelbaum, director of the Clinical Research Division. "Most obviously, he brings a great deal of experience and success in developing models for pancreatic cancer, qualities that we believe will lead to earlier diagnosis and better therapies. Perhaps more importantly, he is a very dedicated, committed researcher who thinks deeply about the general problem of pancreatic cancer. With his addition, I believe the Center is well on its way to becoming one of the nation's leaders for pancreatic cancer research."

Hingorani earned a doctorate in cellular and molecular physiology and a medical degree from Yale University. He completed a clinical fellowship in hematology and oncology at the Dana-Farber Cancer Institute/Brigham and Women's Hospital/Massachusetts General Hospital Cancer Care Program in Boston. He joined the Abramson Family Cancer Center at Penn in 2002, where he worked in the laboratory of Dr. David Tuveson.

GIVE NOW &
SAVE LIVES

Support our quest for cures

For the Media

News releases >
Media coverage >
Contact us >


Story Archive


Publications

Quest
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers


Fred Hutch News

Get updates via email.